Atrium Therapeutics, Inc. (Nasdaq: RNA) reported second-quarter 2026 financial results on August 13, disclosing that the FDA has cleared its Investigational New Drug (IND) application for ATR 1072, its first precision cardiology program to enter human testing, alongside a second $15 million milestone payment earned under its cardiovascular collaboration with Bristol Myers Squibb. The San Diego-based company is developing RNA therapeutics designed to reach the heart directly, targeting rare, genetically driven cardiomyopathies that currently have no approved treatments addressing their underlying cause.

The New Trial: Corventis

The IND clearance lets Atrium launch Corventis, a Phase 1/2 open-label, multicenter trial evaluating ATR 1072 in people with PRKAG2 syndrome. The company also received a No Objection Letter from Health Canada, allowing it to activate planned Canadian trial sites alongside the U.S. ones. Corventis will enroll roughly 37 participants across two parts: Part A uses multiple ascending-dose cohorts to establish safety and pick a dose for further testing, while Part B is a single-arm expansion cohort at that selected dose meant to look for early trends in cardiac structure and function rather than to confirm efficacy outright. That two-part, open-label structure is standard for an early cell or gene-adjacent therapy program, but it also means there is no placebo comparison built into this initial trial, so any early signal in Part B will need to be interpreted cautiously until a larger, controlled study can confirm it. Atrium expects to enroll its first participant by the end of 2026 and to report initial proof-of-concept data in the second half of 2027, so investors should not expect any human efficacy signal from this program before then.

What PRKAG2 Syndrome Is

PRKAG2 syndrome is a rare, inherited heart condition caused by mutations in a gene that regulates a cellular energy-sensing enzyme called AMPK. Those mutations overactivate AMPK, causing abnormal sugar-storage buildup in heart tissue, thickened heart muscle, electrical conduction problems, and arrhythmias. Atrium cites current scientific literature estimating that 1,000 to 2,000 people in the U.S. have the condition, and says no approved therapy currently addresses its underlying genetic cause, leaving only symptom management as an option today.

The Underlying Technology

Atrium’s RNA delivery platform was originally designed at Avidity Biosciences, Inc., and the company describes its approach as combining the tissue-targeting ability of monoclonal antibodies with small interfering RNA, or siRNA, aimed at silencing the disease-causing gene activity directly in heart tissue rather than treating symptoms. The company says this builds on delivery techniques already demonstrated in skeletal muscle and is now being adapted for the heart specifically, though ATR 1072 is the first candidate from this cardiology-focused effort to reach clinical testing, and its real-world safety and efficacy in humans remain unproven.

Second-Quarter Financials

On the financial side, Atrium reported $3.0 million in collaboration revenue for the quarter, down from $3.8 million a year earlier, tied mainly to research services performed under the Bristol Myers Squibb agreement. Research and development expenses rose to $15.3 million from $13.3 million, and general and administrative expenses jumped more sharply, to $10.3 million from $3.4 million, which the company attributes to higher employee-related costs, professional fees, and the expenses of operating as a larger, more established organization. Net loss for the quarter widened to $20.2 million, or $1.18 per share, compared with $12.9 million, or $0.75 per share, a year earlier.

A Balance Sheet in Transition

The balance sheet shows a company that changed shape significantly over the past several months. As of June 30, 2026, Atrium held $280.5 million in total assets and $214.6 million in stockholders’ equity, compared with just $8.4 million in total assets and a $62.7 million deficit attributed to a “Former Parent” as of December 31, 2025. That shift, including cash and short-term investments of $263.9 million as of the most recent quarter, is consistent with Atrium having recently separated from a former parent company into a standalone public entity, though this release does not describe the mechanics or timing of that separation in detail, so no further specifics are available here.

Cash Runway and the BMS Milestone

Atrium says its current cash position, including the newly earned BMS milestone payment, should fund planned operations into mid-2028; that is the company’s own forward-looking estimate rather than a guarantee, and actual spending could differ based on how its trials and pipeline develop. The BMS milestone itself was Atrium’s second payment under the companies’ broader global cardiovascular collaboration, and the release notes it will be reflected in Atrium’s third-quarter financial statements rather than the results reported here, since it was earned in August after the quarter closed.

What’s Next

Beyond Corventis, Atrium’s next disclosed program is ATR 1086 for PLN cardiomyopathy, another rare inherited heart condition, this one caused by mutations affecting a calcium-regulating protein and linked to an estimated 2,000 to 4,000 cases in the U.S.; the company plans to begin IND-enabling studies this year and file that IND in 2027. Atrium also says it is advancing two undisclosed research programs targeting other rare cardiomyopathies, with a further development candidate expected to be selected in 2027. This article covers a quarterly earnings disclosure and regulatory milestone and is not an investment recommendation.

Sources

Atrium Therapeutics Reports Second Quarter 2026 Financial Results, PRNewswire, August 13, 2026.

Editorial Disclosure

This article is based on a press release issued by Atrium Therapeutics, Inc. on August 13, 2026, distributed via PRNewswire. Atrium Therapeutics trades on the Nasdaq under the ticker RNA. BioTech Stocks Daily was not compensated for this coverage. Statements regarding cash runway, trial timelines, the disease-modifying potential of ATR 1072, and future regulatory filings are forward-looking and involve risks and uncertainties; actual results may differ materially, and no data from the Corventis trial has been reported to date. This article is for informational and educational purposes only and does not constitute investment advice. See our full DISCLAIMER.